<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Possible strategies for treating <z:hpo ids='HP_0001297'>stroke</z:hpo> include: 1) thrombolytic therapy with tissue plasminogen activator (tPA): restoring cerebral blood flow in the <z:hpo ids='HP_0011009'>acute</z:hpo> phase of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> but sometimes causing hemorrhagic transformation (HT); 2) stem cell therapy: the repair of disrupted neuronal networks with newly born neurons in the <z:hpo ids='HP_0011010'>chronic</z:hpo> phase of <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Firstly, we estimated the vascular protective effect of a free radical scavenger, <z:chebi fb="0" ids="31530">edaravone</z:chebi>, in the tPA-treated rat model of middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="31530">Edaravone</z:chebi> prevented dramatically decreased the hemorrhagic transformation and improved the neurologic score and survival rate of tPA-treated rats </plain></SENT>
<SENT sid="3" pm="."><plain>Secondly, we attempted to restore brain tissue using a novel biomaterial, polydimethysiloxane-tetraethoxysilane (<z:chebi fb="4" ids="31498">PDMS</z:chebi>-TEOS) hybrid with or without vascular endothelial growth factor (VEGF), and we could show that implantation of a <z:chebi fb="4" ids="31498">PDMS</z:chebi>-TEOS scaffold with VEGF might be effective for treating old <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> or trauma </plain></SENT>
<SENT sid="4" pm="."><plain>In the future, we will combine these strategies to develop more effective therapies for treatment of <z:hpo ids='HP_0001297'>strokes</z:hpo> </plain></SENT>
</text></document>